Fate Uncertain As Cell Therapy Biotech Pulls Out Of J&J Deal, Restructures
Executive Summary
The company is discontinuing its lead clinical programs and planning major layoffs as it seeks to reprioritize its pipeline and extend cash runway.
You may also be interested in...
Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
FDA Lifts Hold On Blueprint’s CDK2 Inhibitor Trial, Potentially Calming Nerves
The FDA placed a partial hold in February amid ocular adverse event concerns, but soon lifted it. Other CDK2 inhibitors have had ocular toxicity issues as well.